Literature DB >> 23633481

Dynamic mast cell-stromal cell interactions promote growth of pancreatic cancer.

Ying Ma1, Rosa F Hwang, Craig D Logsdon, Stephen E Ullrich.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) exists in a complex desmoplastic microenvironment, which includes cancer-associated fibroblasts [also known as pancreatic stellate cells (PSC)] and immune cells that provide a fibrotic niche that impedes successful cancer therapy. We have found that mast cells are essential for PDAC tumorigenesis. Whether mast cells contribute to the growth of PDAC and/or PSCs is unknown. Here, we tested the hypothesis that mast cells contribute to the growth of PSCs and tumor cells, thus contributing to PDAC development. Tumor cells promoted mast cell migration. Both tumor cells and PSCs stimulated mast cell activation. Conversely, mast cell-derived interleukin (IL)-13 and tryptase stimulated PSC proliferation. Treating tumor-bearing mice with agents that block mast cell migration and function depressed PDAC growth. Our findings suggest that mast cells exacerbate the cellular and extracellular dynamics of the tumor microenvironment found in PDAC. Therefore, targeting mast cells may inhibit stromal formation and improve therapy. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23633481      PMCID: PMC3702652          DOI: 10.1158/0008-5472.CAN-12-4479

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

2.  Purification of tryptase from a human mast cell line.

Authors:  J H Butterfield; D A Weiler; L W Hunt; S R Wynn; P C Roche
Journal:  J Leukoc Biol       Date:  1990-05       Impact factor: 4.962

3.  The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells.

Authors:  S Al-Nasiry; N Geusens; M Hanssens; C Luyten; R Pijnenborg
Journal:  Hum Reprod       Date:  2007-02-16       Impact factor: 6.918

4.  Human mast cell tryptase: multiple cDNAs and genes reveal a multigene serine protease family.

Authors:  P Vanderslice; S M Ballinger; E K Tam; S M Goldstein; C S Craik; G H Caughey
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

5.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells.

Authors:  Alain Vonlaufen; Swapna Joshi; Changfa Qu; Phoebe A Phillips; Zhihong Xu; Nicole R Parker; Cheryl S Toi; Romano C Pirola; Jeremy S Wilson; David Goldstein; Minoti V Apte
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

6.  Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4.

Authors:  Sigrid Hatse; Katrien Princen; Gary Bridger; Erik De Clercq; Dominique Schols
Journal:  FEBS Lett       Date:  2002-09-11       Impact factor: 4.124

7.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Authors:  T H Corbett; B J Roberts; W R Leopold; J C Peckham; L J Wilkoff; D P Griswold; F M Schabel
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

Review 8.  The controversial role of mast cells in tumor growth.

Authors:  Domenico Ribatti; Enrico Crivellato
Journal:  Int Rev Cell Mol Biol       Date:  2009       Impact factor: 6.813

9.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Authors:  Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

10.  Pancreatic Cancer: a rare tumor with a devastating health toll.

Authors:  Julie Fleshman
Journal:  Rare Tumors       Date:  2010-09-30
View more
  73 in total

1.  Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling.

Authors:  Ishan Roy; Donna M McAllister; Egal Gorse; Kate Dixon; Clinton T Piper; Noah P Zimmerman; Anthony E Getschman; Susan Tsai; Dannielle D Engle; Douglas B Evans; Brian F Volkman; Balaraman Kalyanaraman; Michael B Dwinell
Journal:  Cancer Res       Date:  2015-09-01       Impact factor: 12.701

Review 2.  Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase.

Authors:  Lawrence M Knab; Paul J Grippo; David J Bentrem
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

3.  Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.

Authors:  Daniel Massó-Vallés; Toni Jauset; Erika Serrano; Nicole M Sodir; Kim Pedersen; Nesrine I Affara; Jonathan R Whitfield; Marie-Eve Beaulieu; Gerard I Evan; Laurence Elias; Joaquín Arribas; Laura Soucek
Journal:  Cancer Res       Date:  2015-04-15       Impact factor: 12.701

Review 4.  Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics.

Authors:  Craig D Logsdon; Thiruvengadam Arumugam; Vijaya Ramachandran
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-09       Impact factor: 4.052

5.  Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment.

Authors:  Sobeyda B Gomez-Chou; Agnieszka Katarzyna Swidnicka-Siergiejko; Niharika Badi; Myrriah Chavez-Tomar; Gregory B Lesinski; Tanios Bekaii-Saab; Matthew R Farren; Thomas A Mace; Carl Schmidt; Yan Liu; Defeng Deng; Rosa F Hwang; Liran Zhou; Todd Moore; Deyali Chatterjee; Huamin Wang; Xiaohong Leng; Ralph B Arlinghaus; Craig D Logsdon; Zobeida Cruz-Monserrate
Journal:  Cancer Res       Date:  2017-03-01       Impact factor: 12.701

6.  Activated pancreatic stellate cells inhibit NK cell function in the human pancreatic cancer microenvironment.

Authors:  Qiang Huang; Mei Huang; Futao Meng; Rui Sun
Journal:  Cell Mol Immunol       Date:  2018-04-08       Impact factor: 11.530

7.  IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.

Authors:  Thomas A Mace; Reena Shakya; Jason R Pitarresi; Benjamin Swanson; Christopher W McQuinn; Shannon Loftus; Emily Nordquist; Zobeida Cruz-Monserrate; Lianbo Yu; Gregory Young; Xiaoling Zhong; Teresa A Zimmers; Michael C Ostrowski; Thomas Ludwig; Mark Bloomston; Tanios Bekaii-Saab; Gregory B Lesinski
Journal:  Gut       Date:  2016-10-21       Impact factor: 23.059

8.  Elastography Can Map the Local Inverse Relationship between Shear Modulus and Drug Delivery within the Pancreatic Ductal Adenocarcinoma Microenvironment.

Authors:  Hexuan Wang; Reem Mislati; Rifat Ahmed; Phuong Vincent; Solumtochukwu F Nwabunwanne; Jason R Gunn; Brian W Pogue; Marvin M Doyley
Journal:  Clin Cancer Res       Date:  2018-10-23       Impact factor: 12.531

Review 9.  Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.

Authors:  Michael Friberg Bruun Nielsen; Michael Bau Mortensen; Sönke Detlefsen
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 10.  Complex role for the immune system in initiation and progression of pancreatic cancer.

Authors:  Kristin S Inman; Amanda A Francis; Nicole R Murray
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.